Katalóg evidencie publikačnej činnosti PU

ID záznamu:	PU.Prešov.2007121211311026
Kategória:	ADC
Autor:	Baum K.A. (16%)
Autor:	O´Leary C.P. (16%)
Autor:	Ferrer F.C. (16%)
Autor:	Klímová Eleonóra (20%)
Autor:	Procházková L. (16%)
Autor:	Bugge J. (16%)
Názov:	Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b [print]
Zdroj:	Multiple Sclerosis : clinical and laboratory research
Lokácia:	Roč. 13, č. 9. - London : SAGE Publications, (2007), s. 1153-1160
ISSN:	1352-4385
Ohlas:	[1] 2009. PORTACCIO, E., AMATO, M.P. Improving compliance with interferon-ß therapy in patients with multiple sclerosis. In CNS drugs, ISSN 1172-7047. 2009, vol. 23, no. 6, s. 453-462.
Ohlas:	[1] 2010. COHEN, J.A., BARKHOF, F., COMI, G. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. In New England journal of medicine, ISSN 0028-4793. 2010, vol. 362, no. 5, s. 415.
Ohlas:	[1] 2009. APPLEBEE, A., PANITCH, H. Early stage and long term treatment of multiple sclerosis with interferon-beta. In Biologics : targets & therapy, ISSN 1177-5475. 2009, vol. 3, s. 270.
Ohlas:	[1] 2010. SAUNDERS, C., CAON, C., SMRTKA, J. et al. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. In Journal of neuroscience nursing, ISSN 0888-0395. 2010, vol. 42, no. suppl. 5, s. S17.
Ohlas:	[1] 2009. TILBERY, C.P., FAZZITO, M.M., JORDY, S.S. et al. Efeitos adversos no tratamento da Esclerose Múltipla com drogas imunomoduladoras – Experiencia em 118 casos. In Revista Neurociencias, ISSN 0104-3579. 2009, vol. 17, no. 3, s. 225.
Ohlas:	[1] 2008. WEBB, U.H. Early interferon beta treatment in multiple sclerosis: Nursing care implications of the BENEFIT study. In Journal of neuroscience nursing, ISSN 0888-0395. 2008, vol. 40, no. 6, s. 356-361.
Ohlas:	[1] 2008. ROSS, A.P. The importance of early treatment: Considerations for multiple sclerosis nurses. In Journal of neuroscience nursing, ISSN 0888-0395. 2008, vol. 41, no. 3, s. E1-E9.
Ohlas:	[1] 2010. DE SÁ, J., URBANO, G., REIS, L. Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. In Current medical research and opinion, ISSN 0300-7995. 2010, vol. 26, no. 9, s. 2237-2242.
Ohlas:	[1] 2010. KOZUBSKI, W. Autoinjector improves injection-related tolerability issues in patients with multiple sclerosis - Exploring the new Extaviject tm 30G system for the injection of interferon beta-1b. In European neurological review, ISSN 1758-3837. 2010, vol. 5, no. 2, s. 81.
Ohlas:	[1] 2008. LEE, C., WONG, P. Management and care – the chnaging landscape of multiple sclerosis. In European neurological review, ISSN 1758-3837. 2008, vol. 3, no. 2, s. 86.
Ohlas:	[1] 2010. PORTACCIO, E., AMATO, M.P. Adherence to interferon beta therapies in multiple sclerosis. In European neurological journal, ISSN 2041-8000. 2010, vol. 2, no. 1, s. 6.
Ohlas:	[3] 2010. MCEWAN, L., BROWN, J., POIRIER, J. et al. Best practices in skin care for the multiple sclerosis patient receiving injectable therapies. In International journal of MS care, ISSN 1537-2073. 2010, vol. 12, no. 12, s. 187.
Ohlas:	[3] 2010. SMITH, B., CARSON, S., FU, R. et al. Drug Class Review: disease-modifying drugs for multiple sclerosis : final update 1 report [online]. Oregon Health & Science University : Portland, 2010 [cit. 2012-05-07], s. 93. Dostupný na internete <http://www.ncbi.nlm.nih.gov/books/NBK50570/>
Ohlas:	[1] 2012. GIOVANNONI, G., SOUTHAM, E., WAUBANT, E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: Tolerability and adherence. In Multiple sclerosis, ISSN 1352-4585. 2012, vol. 18, no. 7, s. 932-946.
Ohlas:	[1] 2012. SINGER, B., BANDARI, D., CASCIONE, M. et al. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferon beta-1a versus subcutaneous interferon beta-1b: results of the randomized, multicenter, Phase IIIb REFORMS study. In BMC neurology, ISSN 1471-2377. 2012, vol. 12, art. no. 154.
Ohlas:	[1] 2013. BOERU, G., MILANOV, I., DE ROBERTIS, F. et al. ExtaviJect 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. In Medical devices : evidence and research, ISSN 1179-1470. 2013, vol. 6, no. 1, s. 175-184.
Ohlas:	[1] 2014. MARZINIAK, M., MEUTH, S. Current perspectives on interferon beta-1b for the treatment of multiple sclerosis. In Advances in therapy, ISSN 0741-238X. 2014, vol. 31, no. 9, s. 931.
Ohlas:	[1] 2014. REDER, A.T., OGER, J.F., KAPPOS, L. et al. Short-term and long-term safety and tolerability of interferon B-1b in multiple sclerosis. In Multiple sclerosis and related disorders, ISSN 2211-0348. 2014, vol. 3, no. 3, s. 294-302.
Ohlas:	[1] 2016. MATHAES, R., KOULOV, A., JOERG, S. et al. Subcutaneous injection volume of biopharmaceuticals -ushing the boundaries. In Journal of pharmaceutical sciences, ISSN 0022-3549. 2016, vol. 105, no. 8, s. 2255-2259.
Ohlas:	[1] 2018. GOLOSHCHAPOVA, E.O., RUNOVA, O.B., USTINNIKOVA, O.B. Recombinant interferons Beta-1a and Beta-1b: Protein structural features and problematic issues with identity confirmation. In Pharmaceutical chemistry journal, ISSN 0091-150X. 2018, vol. 52, no. 8, s. 749-752.
Ohlas:	[3] 2019. BARCUTEAN, L.I., MAIER, S., BAJKO, Z. et al. Interferon beta-1b for the treatment of multiple sclerosis – more than 10 years of experience. In Acta Medica Marisiensis [online], ISSN 2247-6113. 2019 [cit. 2019-05-23], vol. 65, no. 1, s. 18. Dostupný na internete <http://actamedicamarisiensis.ro/interferon-beta-1b-for-the-treatment-of-multiple-sclerosis-more-than-10-years-of-experience/>
Ohlas:	[3] 2020. LAŠČ, N.JU. Aktuaľnosť primenenija preparatov pervoj linii terapii rassejannogo skleroza v sovremennych uslovijach. In Medicinskij sovet : naučno-praktičeskij žurnal dľa vračej [online], ISSN 2658-5790. 2020 [cit. 2021-05-26], no. 19, s. 67. Dostupný na internete <https://www.med-sovet.pro/jour/article/view/5920>
Oblasť výskumu:	180